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Rate of Progression of Coronary
Atherosclerotic Plaque in Women
Stephen J. Nicholls, MBBS, PHD, FRACP, FACC,*†‡ Kathy Wolski, MPH,* Ilke Sipahi, MD,*
Paul Schoenhagen, MD,*§ Timothy Crowe, BS,* Samir R. Kapadia, MD, FACC,*
Stanley L. Hazen, MD, PHD,*†‡ E. Murat Tuzcu, MD, FACC,* Steven E. Nissen, MD, FACC*
Cleveland, Ohio
Objectives The purpose of this study was to determine the relationship between gender and the extent of coronary athero-
sclerosis assessed by intravascular ultrasound (IVUS) and its rate of progression in subjects treated with estab-
lished medical therapies.
Background It is uncertain whether the pathophysiology of coronary artery disease (CAD) differs between genders.
Methods A systematic analysis was performed of 978 subjects who participated in serial studies of atheroma progres-
sion. Genders were compared with regard to the extent of coronary atheroma at baseline and subsequent
change in response to use of established medical therapies.
Results Women were more likely to have a history of hypertension and higher levels of body mass index, low-density lipopro-
tein cholesterol, high-density lipoprotein cholesterol, triglycerides, C-reactive protein, and systolic and diastolic blood
pressure. Despite this, women had less plaque in terms of percent atheroma volume (PAV) (33.9 10.2% vs. 37.8 
10.3%, p  0.001) and total atheroma volume (TAV) (148.7 66.6 mm3 vs. 194.7  84.3 mm3, p  0.001). With
medical therapy, the rate of change of PAV (0.7 0.6% vs. 0.7  0.5%, p  0.92) and TAV (2.3  3.2 mm3 vs.
1.9  2.9 mm3, p  0.84) did not differ between genders. In the setting of intensive risk factor modification, there
was no significant difference between genders with regard to the rates of plaque progression or regression.
Conclusions Despite the presence of more risk factors, the extent of atheroma in women with angiographic CAD is less than
in men in subjects participating in clinical trials that employed serial assessments with IVUS. The finding that the
rate of plaque progression or regression does not differ between genders in the setting of intensive risk factor
modification supports the use of established medical therapies in women with CAD. (J Am Coll Cardiol 2007;
49:1546–51) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.12.039t
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A suboptimal degree of attention has focused
on the detection and management of coronary
artery disease (CAD) in women until recently.
Although many women do not perceive heart
disease as a significant health risk, CAD is the
leading cause of mortality of women in most
eveloped nations (1–3). It remains uncertain whether the
athophysiology of CAD differs in women (4). Although
omen have a lower prevalence of obstructive disease (5–8),
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006, accepted December 5, 2006.hey tend to experience a higher frequency of chest pain
9–11). Their outcome after a clinical event tends to be
orse (6,12–14), a discrepancy that is accentuated with age,
wing to greater prevalence of comorbidities (15). Women
re typically under-represented in clinical trials and are less
ikely to be investigated and receive established therapies in
he setting of acute coronary syndromes (11,16–19).
Although women have less obstructive disease on angiogra-
hy, it remains to be determined whether their absolute burden
f atherosclerotic plaque differs from men. A number of
maging modalities have demonstrated gender differences with
egard to the extent of surrogate markers of plaque burden
20–26). Intravascular ultrasound (IVUS), which precisely
uantifies atheroma burden, has enhanced our understanding
f the factors that influence the natural history of atheroscle-
osis and its response to the use of medical therapies that
odify established risk factors. The purpose of this study is to
etermine whether the burden of atherosclerosis and associated
attern of arterial remodeling is influenced by gender in a
ohort of subjects with angiographic CAD and whether
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April 10, 2007:1546–51 Gender and Plaque Progressionender influences the effect of anti-atherosclerotic therapies
n the rate of plaque progression.
ethods
election of subjects. All subjects who participated in serial
VUS studies of coronary plaque progression (REVERSAL
Reversing Atherosclerosis With Aggressive Lipid Lowering
27)], CAMELOT [Comparison of Amlodipine Versus
nalapril to Limit Occurrences of Thrombosis (28)], and
CTIVATE [ACAT Intravascular Atherosclerosis Treat-
ent Evaluation (29)]) were included in the current analy-
is. Gender was incorporated into the matching process for
andomization to treatment groups in each of these studies.
he subjects therefore represented a cohort with established
AD receiving best medical therapy. Because the active
reatment in ACTIVATE was associated with a potentially
etrimental effect on plaque progression, these subjects were
xcluded from analysis. The IVUS images were acquired
ith a standardized methodology and analyzed by the IVUS
ore laboratory at the Cleveland Clinic Foundation. The
nclusion criteria for these studies have been described in
etail previously. Subjects were ages 30 to 75 years and had
ngiographic CAD comprising at least 1 stenosis of a major
picardial coronary artery 20%. A segment containing no
tenosis 50% for at least 30 mm in a vessel that had not
ndergone percutaneous intervention was studied. Bio-
hemical analysis was performed in a central laboratory
Medical Research Laboratory, Highland Heights, Kentucky).
cquisition and analysis of IVUS images. The details of
VUS acquisition and analysis have been described in detail
reviously (27–29). The IVUS catheter was advanced after
he administration of intracoronary nitroglycerin to position
he transducer distal to a side branch. Images were obtained
uring catheter pullback by an automatic pullback device at
rate of 0.5 mm/s and recorded on videotape at 30 frames/s.
bservers, blinded to the experimental details, analyzed
ross-sectional images, spaced 1 mm apart in the pullback
rom a distal to proximal fiduciary site, defined by the
resence of arterial side branches. The leading edges of the
umen and external elastic membrane (EEM) were traced by
anual planimetry with the National Institutes of Health
mage (version 1.62, National Institutes of Health public
omain software, Bethesda, Maryland).
Total atheroma volume (TAV) was determined by sum-
ation of the plaque area, defined as the difference between
EM and lumen area, for all evaluable images (30).
TAV (mm3) (EEMareaLumenarea)
he TAV was subsequently normalized to the length
orresponding to the median number of comparable slices
or each treatment group in view of the variability in the
ength of pullback analyzed between subjects, because this is
etermined by the anatomic location of the side branches,
hich define the fiduciary points (30). 9AVNorm (mm
3)

 (EEMareaLumenarea)
Number of slices in pullback
Median number of slices
in study population
he extent of atherosclerosis was
lso expressed as percent atheroma
olume (PAV), calculated as the
ercentage of the sum of EEM
reas occupied by TAV (30).
AV (%)

 (EEMareaLumenarea)
 (EEMarea)
 100
he atheroma volume in the most
nd least diseased 10-mm seg-
ents was also determined by summating the plaque areas in
he 10 consecutive images that contained the most and least
mount of plaque, respectively.
Normalized volumes occupied by the EEM and lumen
ere calculated in a similar fashion as TAV. A remodeling
ndex was also calculated at the individual slice that con-
ained the greatest plaque area in each pullback. The index
as determined as the ratio of the EEM area at the most
iseased site compared with the EEM area at a reference
oint, defined as the slice within the proximal 10 mm that
ontained the lowest plaque area. Remodeling at that site
as defined as constrictive (index 0.95) or expansive
index 1.05) (31).
tatistical analysis. Continuous variables are expressed as
ean  SD (median), and categorical variables are ex-
ressed as percentages. Results for C-reactive protein
CRP) are expressed as median (interquartile range). Esti-
ates of atheroma burden at baseline and changes in plaque
urden for women compared with men adjusting for covari-
tes were examined with both a fixed- and random-effect
odel to account for the heterogeneity across trials. Ad-
usted changes are expressed as least square mean and SEM
rom the random-effects model (32) after controlling for
actors related to plaque burden and progression (baseline
theroma burden, age, history of hypertension, history of
iabetes, on-treatment low-density lipoprotein (LDL) cho-
esterol, on-treatment LDL cholesterol). This model also
ncluded investigating for a statistical interaction between
enders with regard to the relationship between the change
n PAV and changes in LDL cholesterol, systolic blood
ressure, or CRP. A p value 0.05 was considered signif-
cant. All statistical analyses were performed with SAS
oftware (version 8.0, SAS Institute, Cary, North Carolina).
linical characteristics. Clinical characteristics of subjects
articipating in clinical trials that employed serial assess-
ents by IVUS at baseline are summarized in Table 1. In
his study women were less likely to be Caucasian (83.9% vs.
Abbreviations
and Acronyms
CAD  coronary artery
disease
CRP  C-reactive protein
EEM  external elastic
membrane
HDL  high-density
lipoprotein
IVUS  intravascular
ultrasound
LDL  low-density
lipoprotein
PAV  percent atheroma
volume
TAV  total atheroma
volume2.4%, p  0.001), had a higher body mass index (31.7 
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Gender and Plaque Progression April 10, 2007:1546–51.8 kg/m2 vs. 29.9  5.2 kg/m2, p  0.001), lower body
urface area (1.88  0.20 m2 vs. 2.10  0.19 m2, p 
.001), and more likely to have history of hypertension
80.5% vs. 63.4%, p  0.001). Women were older (58.0 
.0 years vs. 56.8  9.9 years, p  0.09) and more likely to
ave diabetes (23.1% vs. 18.0%, p  0.08), although these
ailed to meet statistical significance. There were no differ-
nces between genders with regard to use of established
ntiatherosclerotic therapies at baseline. Female subjects
lso had higher baseline levels of total cholesterol (221.3 
7.0 mg/dl vs. 199.1  43.8 mg/dl, p  0.001), LDL
holesterol (133.8  41.5 mg/dl vs. 123.3  37.9 mg/dl,
 0.001), HDL cholesterol (48.7 13.2 mg/dl vs. 39.5
.2 mg/dl, p 0.001), triglycerides (195.9 96.6 mg/dl vs.
84.9  107.5 mg/dl, p  0.02), systolic blood pressure
133.9  17.7 mm Hg vs. 130.9  16.4 mm Hg, p 
.015), and CRP (4.8 mg/l vs. 2.6 mg/l, p  0.001).
aseline atheroma burden. The influence of gender on the
xtent of atheroma at baseline is summarized in Table 1.
omen had less atheromatous plaque, reflected by a lower
AV (33.9  10.2% vs. 37.8  10.3%, p  0.001), TAV
148.7  66.6 mm3 vs. 194.7  84.3 mm3, p  0.001), and
ercentage of images that contained plaque (71.2  29.3% vs.
3.2 23.2%, p 0.001). Percent atheroma volume (33.0
Clinical Characteristics and Atheroma Burdenof Subjects at Basel ne Stratified According to G
Table 1 Clinical Characteristics and Atheromof Subjects at Baseline Stratified A
Parameter Female (n
Age (yrs) 58.0 9.0
Caucasian (%) 83.9
Body mass index (kg/m2) 31.7 6.8
Body surface area (m2) 1.88 0.2
Hypertension (%) 80.5
Diabetes (%) 23.1
Metabolic syndrome (%) 37.5
Dyslipidemia (%) 94.0
Smoker (%) 26.3
Previous MI (%) 30.7
Previous CABG (%) 6.0
Previous PCI (%) 58.2
Statin use (%) 40.6
Beta-blocker use (%) 71.3
Aspirin use (%) 91.2
ACE inhibitor use (%) 33.5
Total cholesterol (mg/dl) 221.3 47.
LDL cholesterol (mg/dl) 133.8 41.
HDL cholesterol (mg/dl) 48.7 13.
Triglycerides (mg/dl) 195.9 96.
Systolic blood pressure (mm Hg) 133.9 17.
Diastolic blood pressure (mm Hg) 77.1 9.8
C-reactive protein (mg/l) 4.8 (2.0,
Percent atheroma volume (%) 33.9 10.
Total atheroma volume (mm3)* 148.7 66.
Percent abnormal images (%)† 71.2 29.
Continuous variables are expressed asmean SD (median) and categ
(interquartile range). *Total atheroma volume is normalized to accou
defined as having a maximal plaque thickness 0.5 mm.ACE  angiotensin-converting enzyme; CABG  coronary artery bypass g
MI  myocardial infarction; PCI  percutaneous coronary intervention..1% vs. 37.9  2.0%, p  0.0001) and TAV (153.2  9.7
m3 vs. 189.9  8.6 mm3, p  0.0001) remained lower after
djustment in a multivariate model that included differences
etween genders in terms of body surface area, race, risk
actors, and medication use.
aseline arterial wall remodeling. There was no difference
etween genders with regard to arterial remodeling at the site
hat contained the greatest amount of plaque (0.96  0.22 vs.
.95 0.21, p 0.59). Women were just as likely to undergo
onstrictive remodeling (remodeling index 0.95, 46.3% vs.
8.7%, p 0.53) and expansive remodeling (remodeling index
1.05, 28.9% vs. 28.0%, p  0.79) at the most diseased site.
omen had smaller vessels, demonstrated by a lower EEM
olume (435.4  133.8 mm3 vs. 512.4  163.9 mm3, p 
.001) and lumen volume (276.8  93.0 mm3 vs. 301.7 
08.1 mm3, p  0.002) (Table 2).
ffect of risk factor modification on plaque progression.
he use of antiatherosclerotic therapies and degree of risk
actor control on therapy are summarized in Table 3. On
herapy, women had higher levels of total cholesterol
178.5  33.8 mg/dl vs. 167.7  33.7 mg/dl, p  0.001),
DL cholesterol (49.8  12.3 mg/dl vs. 41.5  9.7 mg/dl,
 0.001), systolic blood pressure (131.9  13.0 mm Hg
s. 129.1  12.8 mm Hg, p  0.003), and CRP (4.0 mg/l
er
urden
ing to Gender
) Male (n  727) p Value
56.8 9.9 (56) 0.09
92.4 0.001
29.9 5.2 (29.0) 0.001
) 2.10 0.19 (2.10) 0.001
63.4 0.001
18.0 0.08
34.9 0.47
93.7 0.84
23.5 0.38
36.2 0.12
3.6 0.10
62.9 0.18
44.4 0.30
70.3 0.76
91.2 0.99
34.0 0.88
.1) 199.1 43.8 (202) 0.001
) 123.3 37.9 (127.4) 0.001
) 39.5 9.2 (38.6) 0.001
) 184.9 107.5 (158) 0.02
) 130.9 16.4 (129.3) 0.015
78.2 9.8 (79) 0.12
2.6 (1.1, 5.4) 0.001
) 37.8 10.3 (37.4) 0.001
.5) 194.7 84.3 (183.7) 0.001
83.2 23.2 (94.7) 0.001
riables as percentages. C-reactive protein result expressed asmedian
eterogeneity of segment length between subjects. †Abnormal imageend
a B
ccord
 251
(57)
(30.5)
0 (1.85
0 (220
5 (137
2 (46.3
6 (180
7 (132
(79)
7.8)
2 (33.3
6 (139
3 (81)
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April 10, 2007:1546–51 Gender and Plaque Progressions. 2.0 mg/l, p  0.001). In addition, women had a lower
iastolic blood pressure (76.1  6.6 mm Hg vs. 77.3  7.2
m Hg, p  0.047). The influence of gender on the rate of
rogression of atherosclerotic plaque and remodeling is sum-
arized in Table 4. When adjusted for differences between
enders that might influence plaque progression there re-
ained no difference between genders with regard to the
hange in PAV (0.7  0.6% vs. 0.7  0.5% in women and
en, respectively, p  0.92) and TAV (2.3  3.2 mm3 vs.
1.9 2.9 mm3 in women and men, respectively, p 0.84),
hen controlling for clinical trial. Women were no more likely
o undergo substantial progression (defined as at least a 5%
ncrease in PAV, relative risk [RR] 1.04 [95% confidence
nterval (CI) 0.88 to 1.23], p  0.62) or substantial regression
defined as at least a 5% increase in PAV, RR 1.02 [95% CI
.77 to 1.34], p  0.89) throughout the pullback.
ntensive risk factor modification and plaque progres-
ion. The effect of intensive pharmacological modification
f a number of risk factors on plaque progression is
ummarized in Figure 1. Female subjects were just as likely
s male subjects to undergo substantial regression (defined
s 5% reduction in PAV compared with baseline) in the
vent that LDL cholesterol was lowered below 80 mg/dl
26.0% vs. 25.0%, p  0.86), systolic blood pressure below
20 mm Hg (20.4% vs. 21.9%, p  0.81), and CRP below
aseline Remodeling of Subjects atStratifi d According to Gender
Table 2 Baseline Remodeling of Subjects atBaseline Stratified According to Gender
Parameter Female (n  251) Male (n  727) p Value
Remodeling
index
0.96 0.22 (0.96) 0.95 0.21 (0.95) 0.59
EEM volume
(mm3)
435.4 133.8 (421.1) 512.4 163.9 (488.8) 0.001
Lumen volume
(mm3)
276.8 93.0 (260.4) 301.7 108.1 (284.6) 0.002
esults are expressed as mean  SD (median). Remodeling index calculated as the ratio of the
xternal elastic membrane (EEM) area at the site containing the greatest plaque area to the EEM
rea at a reference site containing the least amount of plaque within the proximal 10 mm.
Use of Established Medical Therapies and DegreRisk Factor Control of Subjects Stratified Accor
Table 3 Use of Established Medical TherapiRisk Factor Control of Subjects Str
Parameter Female (n
Therapy
Statin (%) 97.
Beta-blocker (%) 77.
Aspirin (%) 91.
ACE inhibitor (%) 38.
On-treatment parameters
Total cholesterol (mg/dl) 178.5 33
LDL cholesterol (mg/dl) 95 28
HDL cholesterol (mg/dl) 49.8 12
Triglycerides (mg/dl) 171 98
Systolic blood pressure (mm Hg) 131.9 13
Diastolic blood pressure (mm Hg) 76.1 6.6
C-reactive protein (mg/l) 4.0 (1.0Results are expressed as mean SD (median) and categorical variables as percent
Abbreviations as in Table 1.mg/l (19.2% vs. 22.1%, p 0.58). There was no statistical
nteraction between gender and the relationship between
hanges in PAV and either LDL cholesterol (p  0.97),
ystolic blood pressure (p  0.56), or CRP (p  0.92).
to Gender
d Degree of
d According to Gender
1) Male (n  727) p Value
95.9 0.27
76.0 0.52
96.3 0.0002
41.3 0.41
6.8) 167.7 33.7 (165) 0.001
) 93.3 27.5 (91.7) 0.39
.8) 41.5 9.7 (40.5) 0.001
1.3) 166.6 98.8 (141.6) 0.17
129.1 12.8 (128) 0.003
77.3 7.2 (77) 0.047
2.0 (1.0, 5.0) 0.001
Figure 1 Rate of Progression and Regression
With Intensive Risk Factor Modification
Percentage of female (solid squares) and male (open squares) subjects who
underwent plaque progression (A) or regression (B) with intensive modification
of a number of risk factors resulting in low-density lipoprotein (LDL) 80
mg/dl, systolic blood pressure (SBP) 120 mm Hg, or C-reactive protein (CRP)
2 mg/l.e ofding
es an
atifie
 25
2
7
2
8
.8 (17
.8 (93
.3 (47
.2 (15
(131)
(76)
, 7.0)ages. C-reactive protein result expressed as median (interquartile range).
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he current findings provide important insights into our
nderstanding of the impact of gender on the natural history
f atherosclerosis. The results demonstrate that despite the
reater prevalence of risk factors, women contain less
therosclerotic plaque within their coronary arteries. Fur-
her, with the use of established medical therapies, women
erive a similar benefit on plaque progression from intensive
isk factor modification.
These results have implications for the elucidation of the
actors that influence cardiovascular disease in women. It
emains to be established whether there are any gender-
pecific differences in the pathophysiology of atherosclero-
is. The traditional view has proposed that clinical events
ypically begin later in life in women, which is attributed to
he protective influence of endogenous estrogen. However,
number of studies that have employed either direct
easures or surrogate markers have demonstrated the pres-
nce of coronary atherosclerosis in many premenopausal
omen (20–26). In the current study of subjects with
ngiographically evident CAD, women harbored less coro-
ary atheroma. It remains to be determined whether the
elative contribution of plaque extent and activity to the
ncidence of clinical events differs between genders.
The current finding suggests that the relationship be-
ween the risk factor profile and plaque burden might differ
etween genders. Given that the correlation between indi-
idual risk factors and the extent of coronary atheroma is not
trong (33), it is likely that a cluster of risk factors is more
mportant. Despite the greater prevalence of established risk
actors, women harbored less plaque. This raises the possi-
ility that the potential atherogenicity of specific risk factors
r their clusters differs between genders. It is unlikely that
ubstantial differences in arterial remodeling contributed to
he difference in amount of atheroma. Despite the finding
hat vessel size was predictably smaller in women, PAV,
hich expresses plaque burden as a proportion of vessel size,
emained smaller. Furthermore, the pattern of arterial re-
odeling at the site that contained the greatest amount of
laque did not differ between genders.
This study also demonstrated that women are likely to
erive similar benefit from the use of medical therapies that
Serial Changes in Atheroma Burden and Remodto a Hig Us of Es ablished Medical Therapies
Table 4 Serial Changes in Atheroma Burdento a High Use of Established Medic
Parameter Female
Percent atheroma volume (%) 1.20
Adjusted percent atheroma volume (%)* 0.55
Total atheroma volume (mm3) 2.04
Adjusted total atheroma volume (mm3)* 2.49
Atheroma volume worst 10 mm (mm3) 1.10
Atheroma volume best 10 mm (mm3) 2.26
Remodeling index 0.03
Results are expressed as mean  SD (median). *Adjusted changes
differences in factors that influence plaque progression (baseline athe
low-density lipoprotein cholesterol, on-treatment high-density lipoprotesult in intensive risk factor modification. Women are less wikely to seek medical attention and to receive established
herapies in the settings of acute coronary syndromes
11,16–19). The current finding that women receive the
ame benefit of intensive risk factor modification on plaque
rogression supports the recently reported evidence-based
uidelines for cardiovascular disease prevention in women
y the American Heart Association (11).
A number of important caveats should be noted. The
urrent analysis is derived from a post hoc study of 3
eparate clinical trials in combination. However, every
VUS pullback was analyzed in the same core laboratory
ith a standardized protocol. All subjects, by definition, had
ngiographic CAD. Although the current findings relate to
he use of medical therapies for secondary prevention, there
s no evidence to support a restriction of primary prevention
trategies in women. Similarly, all subjects met the criteria
nd had consented to participate in a clinical trial. It is
ncertain whether the same findings would be observed in
he general population presenting for diagnostic angiogra-
hy. Only 1 coronary artery was studied in each subject. It
s possible that the extent of atheroma throughout the
oronary tree is not uniform and that the extent of plaque
emonstrated in an artery does not reflect the patient’s
laque burden in general. It is also not known whether the
ate of progression of atherosclerosis is linear or character-
zed by abrupt changes in atheroma burden. The require-
ent for an invasive procedure limits the number of times
hat IVUS can be performed. It would be of interest to
erform future studies with evolving noninvasive imaging
odalities such as computer tomography and magnetic
esonance imaging. The studies are also susceptible to
election bias. It is possible that women required more risk
actors to warrant an indication to proceed to coronary
ngiography. In addition, IVUS is limited in its ability to
haracterize plaque composition. As a result, it is not
ossible to determine whether gender influenced either the
omposition of plaque at baseline or its modification in
esponse to established antiatherosclerotic therapies. The
ndividual trials differed widely with regard to collection of
ata with regard to menopausal status, exogenous hormone
se, or hormone levels. The potential influence of estrogen
n the observed findings should also be considered and
of Subjects in Responseified Ac ord g to Gender
Remodeling of Subjects in Response
erapies Stratified According to Gender
251) Male (n  727) p Value
(0.57) 0.87 4.06 (0.68) 0.28
0.86 0.16 0.35
(0.60) 0.05 26.8 (1.14) 0.28
0.45 1.02 0.33
(0.72) 2.02 11.9 (2.07) 0.29
.25) 1.64 9.4 (1.0) 0.36
(0.03) 0.03 0.15 (0.03) 0.88
nt atheroma volume and total atheroma volume take into account
urden, age, history of hypertension, history of diabetes, on-treatment
lesterol, and study) expressed as least-squares mean  SEM.elingStrat
and
al Th
(n 
4.56
0.28
25.1
1.81
10.8
8.0 (1
0.17
in percearrants further investigation. Similarly, it is uncertain
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April 10, 2007:1546–51 Gender and Plaque Progressionhether the genders differed with regard to the duration of
se of established medical therapies before enrollment in the
linical trials.
In summary, the current study of patients with angio-
raphic CAD demonstrated that women harbor less ath-
rosclerotic plaque within their coronary arteries, despite the
reater prevalence of atherogenic risk factors. Furthermore,
ntensive risk factor modification in response to the use of
stablished medical therapies has a similar influence on
laque progression in both men and women. These results
dd further support for the promotion of aggressive preven-
ive measures to prevent morbidity and mortality from
therosclerotic cardiovascular disease in women.
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